Skip to main content

Table 4 Toxicities of imatinib combined with chemotherapy in human cancers

From: Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide

References

N

Treatment protocol

Main toxicities

40

30

STI 400 mg/d + AraC 20 mg/m2/d15–28.

* Hematologic.

* Nausea-vomiting.

* Fatigue.

* Abdominal pain.

* Edema.

41

22

STI 300–800 mg/d + anagrelide 0.5–4 mg/d.

* Hematologic.

* Peripheral edema.

* Fatigue.

* Skin rash.

42

28

STI 600 mg/d + docetaxel 20–45 mg/m2/d1,8,15,22.

* Hematologic.

* Nausea.

* Fatigue.

43

20

STI 400 mg/d + hyper-CVAD.

* Hematologic.

* Infections.

44

30

STI 400 mg/d + hydroxyurea 1 g/d.

* Edema.

* Abdominal pain.

45

20

STI 400/600 mg/d + daunorubicin 50 mg/m2/d1–3 + vincristine 2 mg d1,8,15,22 + prednisolone 60 mg/m2/d1–28 + L-asparaginase 4000 U/m2/d17–28.

* Hematologic.

* Hyperbilirubinemia.

46

33

STI 400/500 mg/d + hydroxyurea 1 g/d.

* Hematologic.

47

9

STI 300–400 mg/d + doxorubicin 50–60 mg/m2/d1.

* Hematologic.

* Nausea-vomiting.

* Reduction of LVEF.

* Fatigue.

47

7

STI 300–400 mg/d + gemcitabine 700–800 mg/m2/d1,8,(15).

* Hematologic.

* Fatigue.

48

9

* STI 300–600 mg/d + irinotecan 65 mg/m2 d1,8 + cisplatin 30 mg/m2 d1,8.

* STI 300–800 mg/d + irinotecan 60 mg/m2 d1,8,15 + cisplatin 60 mg/m2 d1.

* Hematologic.

* Diarrhea.

* Thrombosis.

* Electrolyte disorder.

49

31

STI 800 mg/d + vincristine 2 mg d1,8,15,22 + dexamethasone 40 mg d1,2,8,9,15,16,22,23.

* Hematologic.

* Infections.

* Neuropathy.

50

80

STI 600 mg/d + cyclophosphamide 1200 mg/m2/d1 + daunorubicin 50 mg/m2/d1–3 + vincristine 1.3 mg/m2/d1,8,15,22 + prednisolone 60 mg/m2/d1–21.

* Hematologic.

* Nausea.

* Liver dysfunction.

  1. Abbreviations: Hyper-CVAD, cyclophosphamide + vincristine + doxorubicin + dexamethasone + methotrexate + cytarabine; LVEF, left ventricular ejection fraction.